Lupin Ltd. Share Price

Lupin Launches Ranibizumab Biosimilar Across Europe

LUPIN : Lupin Limited has announced the European launch of its biosimilar ranibizumab, marketed under the brand name Ranluspec™, with Sandoz Group AG partnering to distribute the product across the European Union, excluding Germany. The launch marks an important commercial development for Lupin's biotechnology business and expands the availability of its biosimilar treatment for patients with retinal diseases. Ranibizumab is a biosimilar medicine used in the treatment of several retinal conditions, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), proliferative diabetic retinopathy (PDR) and choroidal neovascularization . Under the partnership arrangement, Sandoz will oversee the commercialisation and distribution of Ranluspec™ in the designated European markets, while Lupin is responsible for manufacturing and regulatory submissions. Germany is excluded from the stated European distribution arrangement. The launch represents a step forward in commercialising Lupin's biosimilar portfolio through an established international pharmaceutical partner. The development also highlights Lupin's presence in the global biologics and biosimilars market, particularly in ophthalmology. Expanding access to biosimilar medicines can provide additional treatment options for healthcare providers and patients. Market participants may track the commercial rollout, market reach and further developments related to the product and the company's biotechnology portfolio. Overall, the European launch of Ranluspec™ through Sandoz represents a notable business update for Lupin, supporting its international biosimilar expansion and access to treatments for retinal diseases. This information is shared strictly as a corporate and market update for informational purposes and should not be considered investment advice, research analysis, or a recommendation to buy or sell any security.

Lupin: Complex generics and specialty medicines drive growth

LUPIN Lupin: Complex generics and specialty medicines drive growth Lupin Limited (NSE: LUPIN) is strengthening its presence across respiratory therapies, complex generics and specialty pharmaceuticals, with opportunities in both domestic and international markets. **Why it matters:** Complex generics and specialty products can offer better growth opportunities than conventional formulations. However, regulatory approvals, pricing pressure in the US market and competition from generic manufacturers can affect profitability. **My view:** Lupin's long-term performance depends on sustaining its respiratory franchise while expanding its specialty and complex-generic portfolio. Product launches need to translate into meaningful market share, revenue growth and improved margins. **What to watch:** US formulation sales, respiratory product performance, new product approvals, domestic growth, research and development spending and operating margins. **Stance:** The specialty and complex-generics opportunity is encouraging, but consistent execution, regulatory progress and sustainable profitability remain key to the investment case. Disclosure: I am a SEBI Registered Research Analyst. This content is for educational purposes and is not a recommendation to buy or sell any security.

Nifty Pharma at Triangle Reference; RSI Caution

Nifty Pharma has broken out of its long triangle consolidation on the weekly chart and extended the rally. The index is now near 28,900, with a weekly high around 29,225. That is close to the measured-move reference of about 29,200 from the triangle breakout. RSI at about 73 shows strong momentum, but it is also forming a negative divergence, with price making higher highs while RSI makes lower highs. A similar setup was seen around September 2024, after which the index corrected. A negative divergence is only a caution and not a reversal signal by itself. A reversal candlestick near the top would add weight to the caution, and until then caution is the operative word. The 200-week SMA near 20,160 is far below, so the broader trend remains intact, but after a sharp advance, consolidation or profit booking would not be unusual. Heavyweights such as SUNPHARMA , Cipla, Dr. Reddy’s, Lupin and Divi’s Laboratories are worth tracking for how they behave from here. The weekly candle is still forming, so the closing structure matters. The weekly candle is still forming, so the closing structure matters. Negative RSI divergence at a pattern’s measured-move reference is a caution, not a sell signal; a reversal candlestick at the top gives it more weight. Disclaimer: This is for educational purposes only and is not investment advice. Please consult your financial advisor before making any investment decisions. SEBI Registered Research Analyst — INH000025212.

Lupin Q2 profit falls 22% as margins contract

Lupin Limited (NSE: LUPIN) reported Q2 FY27 sales of ₹7,785.5 crore, up 14% year-on-year. However, consolidated profit after tax declined 22.2% to ₹1,155.3 crore. EBITDA fell 10.7% to ₹2,171.2 crore. EBITDA margin declined from 35.6% to 27.9%, a contraction of 770 basis points. The decline came despite higher sales. The key concern is the gap between revenue growth and profit growth. Employee costs increased 28.8% year-on-year, while manufacturing and other expenses increased 23.2%. Depreciation and impairment expenses also rose 53.4%. These cost increases need to be monitored because they are reducing the benefit of higher sales. India sales grew 14.7%, while US sales increased 9.3%. Other developed markets recorded stronger growth of 45.7%. This indicates that demand remains supportive across important markets, but cost control is now central to earnings performance. My view: Lupin's revenue growth remains healthy, but the margin decline makes the quarter mixed rather than unambiguously positive. The next result should be assessed for recovery in EBITDA margin and moderation in operating expenses. What to watch next: EBITDA margin, employee cost as a percentage of sales, and US business growth in Q3 FY27. Stance: Track margin recovery before drawing a stronger conclusion on earnings momentum. LUPIN

Lupin Profit Falls 22% Despite Strong US Business Growth

LUPIN has reported a mixed Q2 FY27 performance, and there's an important detail investors should not overlook. The pharmaceutical company reported a 22.2% year-on-year decline in consolidated net profit to ₹1,155 crore. However, revenue increased 11.1% to ₹7,827 crore. But here's an interesting development. Lupin launched Raltegravir Tablets USP 600 mg in the US after receiving approval from the US FDA. The company is the exclusive first-to-file applicant and is eligible for 180 days of generic drug exclusivity. Why does this matter? Generic drug exclusivity can provide a temporary competitive advantage, allowing a company to capture market share before other generic competitors enter. For Indian pharmaceutical companies, the US market is important because successful product launches can create additional revenue opportunities. However, investors should also track pricing pressure, competition and the sustainability of US business margins. For me, the interesting part of Lupin's story is the contrast between declining quarterly profit and new opportunities in the US generics market. The next few quarters will show whether new launches can translate into stronger earnings growth.

LUPIN: US GENERICS AND PRODUCT PIPELINE IN FOCUS

LUPIN is worth tracking as investors assess its September-quarter results and outlook for the pharmaceutical business. The company has exposure to the Indian pharmaceutical market as well as international markets, particularly the United States. Key factors to monitor: - US formulation sales - Domestic formulation growth - Product approvals and launches - Regulatory compliance and manufacturing updates - Research expenditure and operating margins My view: The pharmaceutical business offers opportunities through new product launches and international expansion, but pricing pressure and regulatory risks remain important. Investors should focus on the quality and sustainability of earnings rather than revenue growth alone. The quarterly results and management commentary will be important for understanding the next phase of performance. Research disclosure : This content is for informational and research purposes only and should not be construed as personalised investment advice. Investors should conduct their own due diligence and consider their risk tolerance before making investment decisions.